Class Action Lawsuit Filed Against ImmunityBio Securities

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 1 hour ago

0mins

IBRX-8.55%

Should l Buy IBRX?

Source: Globenewswire

Class Action Initiation: Rosen Law Firm has filed a class action lawsuit against ImmunityBio (NASDAQ: IBRX) for securities purchased between January 19 and March 24, 2026, aiming to seek compensation for investors, highlighting the legal risks faced by the company.
Compensation Structure: Investors participating in the lawsuit can receive compensation without any upfront costs through a contingency fee arrangement, demonstrating the law firm's commitment to protecting investor rights and its expertise in securities litigation.
False Statement Allegations: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to significant misrepresentations regarding the company's business and prospects, which could result in investor losses and indicate potential governance issues.
Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on IBRX

Wall Street analysts forecast IBRX stock price to fall

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.070

Low

5.00

Averages

7.33

High

9.00

Current: 8.070

Low

5.00

Averages

7.33

High

9.00

BTIG

Buy

initiated

$13

2026-03-11

Reason

BTIG

Price Target

$13

AI Analysis

2026-03-11

initiated

Buy

Reason

BTIG assumed coverage of ImmunityBio with a Buy rating and $13 price target. The stock has had a strong start to 2026, rising 318% year-to-date driven by 700% y/y growth for ANKTIVA in the US, EU conditional marketing approval, and approval for NSCLC in Saudi Arabia, and the firm believes further share appreciation from here will be led by continued ANKTIVA commercial execution and label expansion, the analyst tells investors in a research note.

Piper Sandler

NULL

Overweight

upgrade

$7 -> $12

2026-03-04

Reason

Piper Sandler

Price Target

$7 -> $12

2026-03-04

upgrade

NULL

Overweight

Reason

Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and keeps an Overweight rating on the shares. The firm notes U.S. ANKTIVA net revenues grew about 700% to $113M in 2025, and Piper now projects $195M in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IBRX

Unlock Now

About IBRX

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

IMMUNITYBIO INC PLANS TO FILE SUPPLEMENTAL BLA BY 2026

15 hours agomoomoo

Community Bio Initiative: The initiative focuses on submitting supplemental information to enhance community engagement and support.
Contractual Framework: The project is structured under a contract that outlines the responsibilities and expectations for all parties involved.
Timeline for Submission: The goal is to have all supplemental materials submitted by the year 2026.
Impact on Local Development: The initiative aims to foster local development and improve community resources through collaborative efforts.

IBRX Stock Rebounds: Anktiva Shifts Focus to Severe Pneumonia Following Successful Bladder Cancer Trial Milestone

1 day agostocktwits

Bladder Cancer Study Update: A Phase 3 bladder cancer study has reached a key efficacy endpoint, prompting a review by an independent monitoring committee. The trial is comparing a combination therapy of Anktiva and BCG against BCG alone in newly diagnosed patients.
Stock Performance: Shares of Immunity Bio (IBRX) surged by about 9% following the announcement of new trials and progress in their bladder cancer study, recovering from a previous sharp sell-off.
New Trials for Severe Pneumonia: Immunity Bio has initiated new studies evaluating Anktiva in combination with off-the-shelf immune cell therapy for critically ill patients with severe pneumonia, aiming to improve immune function and survival rates.
Market Sentiment: Retail sentiment for IBRX has shifted positively, with significant increases in message volumes, indicating growing investor interest and optimism about the company's potential in cancer therapies.

ImmunityBio Shares Decline Following FDA Alert: Drug Not Capable of 'Treating All Cancers.'

2 days agoBarron's

FDA Action: The Food and Drug Administration (FDA) accused ImmunityBio of using false or misleading advertising for its bladder cancer drug, Anktiva.
Market Reaction: Following the FDA's announcement, shares of ImmunityBio experienced a significant decline.

IBRX Shares Drop 25% Following FDA's Warning on 'Misleading' Marketing of Bladder Cancer Treatment ANKTIVA

2 days agostocktwits

FDA Warning: Immunity Bio's shares dropped nearly 25% after the FDA issued a warning letter regarding misleading promotional communications for its bladder cancer treatment, ANKTIVA.
Misleading Claims: The FDA highlighted that advertisements made strong claims about ANKTIVA's ability to "treat all cancers," which the agency deemed misleading.
Response Required: The FDA has requested Immunity Bio to respond within 15 days to address the misleading promotions and warned of potential legal action for non-compliance.
Impact on Company: The warning and subsequent stock drop reflect concerns over the company's marketing practices and the implications for its product's credibility in the market.